-+ 0.00%
-+ 0.00%
-+ 0.00%

BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est

Benzinga·08/05/2026 11:05:35
語音播報
BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $666.201 million estimate.